This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

Phase 1 Recruiting 55 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences Gracell Biotechnologies (Shanghai) Co., Ltd. · collab

NaSequentialOpen-labelTreatment

Summary

This is a First-in-Human, open-label, early dose-escalation clinical study to evaluate the safety and preliminary efficacy of GC511B CAR T cell injection in Adult with DLL3+ r/r SCLC trial participants.

Timeline

Start: 2026-03-03
Primary completion: 2026-11-10
Completion: 2028-12-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GC511B	Cell therapy	—	Intravenous

This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

Summary

Timeline

Drugs

Indications